Validity Of Patient-Reported Outcomes From Columbus, A Randomized Open Label Phase Iii Clinical Trial Of Encorafenib Plus Binimetinib VS Vemurafenib In Advanced Braf-Mutant Melanoma
May 1, 2018, 00:00 AM
10.1016/j.jval.2018.04.318
https://www.valueinhealthjournal.com/article/S1098-3015(18)30618-1/fulltext
Section Title :
Section Order :
1087
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30618-1&doi=10.1016/j.jval.2018.04.318